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INTRODUCTION
Cancer or malignancy is a disease which marked
with an abnormal growth and spread of tissue. Cer-
vical carcinoma is still the second most common
malignancy causing death in the world. Geographi-
cally, it is still more commonly found in developing
country. More than 80% of the cases were found
in low-income countries in Africa, Melanesia, Latin
America, Middle Asia and South East Asia.1
In the United Stated, cervical cancer is the third
most common gynecological malignancy, responsi-
ble for 20% of all malignancy. In 1994, there were
approximately 15,000 newly diagnosed patients
and 4,600 deaths.2
The incidence of cervical cancer in Indonesia
ranged at 100-190 out of 100,000 people per year.
But until now, the survival rate has only reached
52%. To improve the outcome of treatment, new
studies focused on finding new management stra-
tegy are needed. One of the best strategy for cancer
management is to induce apoptosis.2
Abstract
Objective: To observe the success of platinum, vincristin, bleomycin
and mitomycin C (PVB-MMc) combination chemotherapy on cervi-
cal carcinoma by evaluating apoptosis feature.
Methods: This study was performed at Dr. Wahidin Sudirohusodo
Hospital and several other hospitals. The method of this study was
prospective longitudinal. Cervical biopsy was performed on 15 cer-
vical carcinoma patients before and after PVB-MMc chemotherapy.
Six patients were at early stage and 9 patients were at advanced
stage. Biopsy result were sent to pathologic anatomic laboratory to
be made into paraffin block and further examined for apoptosis with
Tunel method. Data were analyzed by using Wilcoxon Signed Rank
test.
Results: Study results indicating no significant difference for apop-
tosis index before and after PVB-MMc chemotherapy for early stage
(p=0.463), advance stage (p=0.594), but quantitatively there were
increasing apoptosis index before and after chemotherapy.
Conclusion: Chemotherapy combination PVB-MMc for cervix carci-
noma can increase apoptosis index and give a good response in term
of reducing the tumor size although statistically not significant.
[Indones J Obstet Gynecol 2012; 36-4: 200-5]
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chemotherapy.
Abstrak
Tujuan: Penelitian ini bertujuan mengetahui keberhasilan kemo-
terapi kombinasi platosin, vincristin, bleomisin dan mitomisin C (PVB-
MMc) pada karsinoma serviks dengan menilai gambaran apoptosis.
Metode: Penelitian ini dilakukan di BLU RS Dr. Wahidin Sudirohusodo
dan jejaring. Metode penelitian yang digunakan adalah longitudinal
prospektif. Dilakukan biopsi serviks terhadap 15 pasien karsinoma
serviks sebelum dan sesudah kemoterapi PVB-MMc. Enam pasien sta-
dium dini dan sembilan stadium lanjut. Hasil biopsi dikirim ke labora-
torium Patologi Anatomi untuk dibuat blok parafin dan selanjutnya
apoptosis diperiksa dengan metode Tunel. Data dianalisis dengan
menggunakan uji Wilcoxon Signed Rank test.
Hasil: Hasil penelitian ini menunjukkan tidak ada perbedaan ber-
makna indeks apoptosis sebelum dan sesudah kemoterapi PVB-MMc
pada stadium dini (p=0,463), stadium lanjut (p=0,594), tetapi secara
kuantitatif ada peningkatan indeks apoptosis sebelum dan sesudah
kemoterapi.
Kesimpulan: Pemberian kemoterapi kombinasi PVB-MMc pada karsi-
noma serviks dapat meningkatkan indeks apoptosis dan memberi
respons klinik yang baik terhadap perubahan ukuran tumor walau-
pun secara statistik tidak bermakna.
[Maj Obstet Ginekol Indones 2012; 36-4: 200-5]
Kata kunci: apoptosis, kanker serviks, kemoterapi kombinasi PVB-MMc.
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Recently, studies in the field of cancer is focused
on identifying apoptosis involved in tumor devel-
opment and observing the outcome of therapy.
Apoptosis or cell-death program is a program con-
trolling physiologic growth of cell and balancing
tissue development.
Common strategy performed in clinical oncology
to eliminate tumor cells are chemotherapy, radia-
tion and immunotherapy. These strategies are as-
sociated with activating transduction for apoptosis
signal. Cells failing to undergo apoptosis shows that
cells are resistent to treatment.3,4
Cancer cell’s ability to respond to chemotherapy
is a part of its apoptosis capacity. The regulation
of apoptosis could influence the resistency towards
chemotherapy, thus influence the outcome of treat-
ment. Effectivity of several chemotherapy drugs
are very depended on the ability of cancer cell to
undergo chemotherapy-induced apoptosis.2
Unlike radiation and surgery, chemotherapy is a
treatment of cancer using drugs or hormone. Che-
motherapy could be used in both localized or me-
tastized lesion. In the beginning, chemotherapy is
only a palliative treatment, but recently it was
found that several type of cancers could be treated
with chemotherapy.
The use of combination chemotherapy has
shown significant succeed, especially in the combi-
nation of drugs with different mechanism of action.
The advance of treatment in several type of cancer
is achieved by using several types of drugs sequen-
tially.5
Chemotherapy could be curative or palliative,
and could act both regionally or systemic. The du-
ration of chemotherapy regiment is different, de-
pending on whether it is meant for palliative or
curative purpose. For palliative regiment, evalu-
ation is performed on the second cycle. Meanwhile,
neoadjuvant chemotherapy is given in 12-18 weeks,
with recovery period of 4-6 weeks.6
The treatment of advanced stage cervical cancer
in Makassar is mainly by neoadjuvant chemother-
apy, due to inadequate radiotherapy facilities. The
regiment currently being used is the combination
of 3 drugs, namely cisplatin, vincristin, and bleomi-
cin (PVB) or 4 drugs, with an additon of mitomycin C.
Vogl et al reports a response rate of 77% on the
use of neoadjuvant chemotherapy (PVB-MMc). The
effectivity of the regiment has also been proven by
Gynecological Cancer Group (GCG) from EORTC in
squamos cell cervical carcinoma with the following
dose: bleomycin 30 UI, vincristine 0.5 mg/m2, mi-
tomycin-C 10 mg/m2 and cisplatin (platosin) 50
mg/m2. PVB-MMc dose currently used in Makassar
is bleomycin 30 UI, vincristine 0.5 mg/m2, mitomy-
cin-C 20 mg/m2 and cisplatin 50 mg/m2. The cum-
mulative dose of mitomycin-C can’t be more than
50 mg/m2 in combination chemotherapy.7
Sharviyanti et al performed study in 71 ad-
vanced stage cervical cancer patients. There were
29 cases (40.85%) became operable after 2 series
of chemotherapy, but 42 cases (59.15%) remained
inoperable. From 29 cases became operable, 22
cases (75.9%) gave complete response with his-
topathology examination showed no malignant cell
in cervix, uterus, adnexa and lymph node. And 7
cases (24.1%) still shows partial response and ma-
lignant cells were still found. From 42 cases re-
mained inoperable, 2 (4.77%) were non responsive
and 40 other cases (95.23%) gave partial response
because the tumor used to be very exophitic and
bulky (diameter > 4 cm) had reduced in size but
there were still process in the parametrium. There
was no severe toxic response from this research.8
Based on this research, we saw the need for fur-
ther studies for PVB-MMc regiments, mainly to see
the effect it has on the apoptosis of cancer cells.
METHOD
This study was performed in the Institutional Hos-
pital Department of Obstetrics and Gynecology,
Faculty of Medicine, University of Hasanuddin, Ma-
kassar. Dr. Wahidin Sudirohusodo Hospital and the
satellite hospitals, from March 2011 until February
2012. The method of this study was prospective
longitudinal, aimed to observe the relationship be-
tween combination chemotherapy regiment of Pla-
tinum, Vincristin, Bleomycin and Mitomycin C with
apoptosis index in the cervical cancer patients.
The subject of this study was patients diagnosed
as having cervical cancer in Dr. Wahidin Sudiro-
husodo Hospital or other satellite hospitals, and
planned to receive combination chemotherapy regi-
ment of Platinum, Vincristin, Bleomycin and Mi-
tomycin C. Subject must agree to join the study and
fulfilled the inclusion criteria. Data was acquired by
performing anamnesis, physical and laboratory ex-
amination, and histopathology examination, and
immunohistochemical examination to detect apop-
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tosis cells with TUNEL (T-UTP Nick End Labeling)
method using In Situ Cell Death Detection kit Apop-
Tag® in paraffin block tissue preparation.
Data will be categorized and analyzed using
SPSS for window version 17. The analysis was per-
formed using Wilcoxon Signed Ranks Test and the
result would be considered significant if p ≤ 0.05.
RESULT
His study was performed on 15 patients who un-
dergone two times cervical biopsy, once before and
once after the chemotherapy. The tissue will be fix-
ated in 10% formalin and then sent to Pathology
anatomy laboratorium to be processed into paraf-
fin block preparation and examined to detect apop-
tosis with TUNEL method.
Subject Characteristic
The characteristic of the subjects was summarized
in Table 1.
Table 1. Subject Characteristics
Variable Frequency Percentage
(%)
Age group
≤ 45 years old
> 45 years old
 5
10
33.33
66.67
Parity
Primipara
Multipara 
 0
15
  0  
100  
Educational background
Elementary school
Junior high school
Senior high school
 4
 4
 7
26.67
26.67
46.66
History of contraception
None
DMPA
IUD 
 5
 7
 3
33.33
46.67
20.00
Stage
Early
Advance
 6
 9
40.00
60.00
Histopathology
Squamous cell
Adenosquamous
Adenocarcinoma
10
 3
 2
66.67
20.00
13.33
In Table 1, we could see that most patients were
in over 45 years old group (66,67%), with the
youngest patient being 30 years old and the oldest
being 65 years old. According to parity, all pa-
tients were multiparous, with 2-8 children. Most
patients graduated senior high school (46.66%).
The most common contraception used by subject
was DMPAs (46.67%).
Most cases were in advanced stage (60%) and
the most common histopathologic type was
squamous cell carcinoma (66.67%).
The effect of chemotherapy in apoptosis index
and tumor size in early stage cancer.
Table 2. The difference in apoptosis index and tumor size
before and after chemotherapy in early stage cancer
Variable n p*
Apoptosis index
Increasing
Decreasing
No change
4
2
0
0.463
Tumor size
Increasing
Decreasing
No change
0
6
0
0.026
* Wilcoxon Signed Rank test
In 6 cases of early cervical carcinoma (Table 2)
the apoptosis index showed no significant change
before and after chemotherapy, with p=0.463
(p<0.05). But there were 4 cases with increasing
apoptosis index and 2 cases with decreasing apop-
tosis index, meaning that chemotherapy still showed
effects in apoptosis index quantitatively.
But in all cases, the tumor size reduced signifi-
cantly with p=0.026 (p<0.05), showing significant
effects both clinically and statistically of PVB-MMc
in tumor size.
The effect of chemotherapy in apoptosis
index and tumor size in advanced stage
cancer
Table 3. The difference in apoptosis index and tumor size
before and after chemotherapy in advanced stage cancer
Variable n p*
Apoptosis index
Increasing
Decreasing
No change
6
3
0
0.594
Tumor size
Increasing
Decreasing
No change
2
3
4
0.498
* Wilcoxon Signed Rank test
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In the patients with advanced stage cancer, out
of 9 cases, there were 6 patients showing increas-
ing apoptosis index while 3 patients showed de-
creasing apoptosis index. Statistical analysis gave
p=0.594 (p>0.05), meaning that chemotherapy in
advanced stage cancer did not show significant re-
sult. But when we looked at the result clinically, 6
cases did show increasing apoptosis index, and it
was a significant number of patients. Thus PVB-
MMc regiment could still be a choice in the treat-
ment of cervical carcinoma.
Based on the tumor size (Table 3), three cases
(33.33%) decreased in size, two cases increased
(22.22%), while the rest four cases (44.44%)
stayed in size. Statistical analysis gave p value of
p=0.498 (p>0.05), meaning that it is statistically in-
significant, but clinically there were seven cases
(77.7%) which responded well to chemothrapy,
thus chemotherapy is still recommended because
it could maintain or even reduce the size of the
tumor.
The most commonly found histopathology type
in this study was squamous cell carcinoma
(66.67%). Almost 70% of all squamous cell carci-
noma cases had an increaseing apoptosis index.
This is similiar with the other histopathology types.
It showed that chemotherapy could increase apop-
tosis index, regardless of the histopathological
type.
DISCUSSION
This study was conducted by taking a biopsy sam-
ple of 15 cervical carcinoma lesion in patients be-
fore and after chemotherapy combination PVB-
MMc fit the inclusion criteria. The first biopsy was
performed before the administration of chemo-
therapy and the second biopsy performed after the
patients undergoing 2 series chemotherapy.
Table 1 shows the characteristics of the data
such as age, parity, education, history of contracep-
tive use, stage and type of carcinoma cells. Most
subjects were over 45 years (66.67%). Turah et al
had the same high percentage of subjects in that
age group (56.7% ).9 Different results were ob-
tained by Sulina, where approximately 43% tof the
subjects were less than 45 years old.10 In the
United States, the average age of women with cer-
vical carcinoma was 52.2 years. Age variation may
be different due to several factors such as not op-
timal screening, socio-economic status, educational
background and the level of knowledge in the com-
munity about the disease.
All subjects had more than 2 children. One of the
risk factors for cervical carcinoma is multiparity.
Sulina et al got the same result, ie 100% of the pa-
tients was multiparous.10 Trauma in labor may be
a predisposing factor for the development of pre-
cancerous lesions that can subsequently become
carcinoma.
Education level of secondary education were
found in 73.3% of the subjects. The different re-
sults were obtained by Turah that most subjects
had only the primary education (56.7%).9
Approximately 66.7% of the subjects had a his-
tory of contraception. Some epidemiological data
showed that hormonal was one of the risk factors.
But keep in mind that the incidence of carcinoma
of the cervix is a complex interaction of several co-
factor.11
Most subjects (60%.) in this studies were at the
advanced stage of the disease. Both Turah and
Sulina found that 50% of the subjects were in ad-
vanced stage. Early signs of cervical carcinoma is
not specific, such as the presence of vaginal secre-
tion, sometimes alongside a spot bleeding. Gener-
ally very minimal signs are often ignored by the
patient so that they come up with an advanced
stage.9,10
According to the histopathological type, squamous
cell carcinoma is the most common type (66.7%)
in this study. Hung obtained the results in 30,989
patients that two-thirds of the patients had
squamous cell carcinoma.
Apoptosis is a programmed cell death occuring
during normal development and the aging process
as a homeostatic mechanism to maintain cell popu-
lations in the tissue.12
Mechanism for apoptotic cell death could occur
via several pathways: 1) through p53. When cells
undergo DNA damage, it activates the p53 gene
which will stop the signal through the p21 CDK
phosphorylation that in turn will stop the cell cycle.
If DNA is not successfully repaired the p53 gene
will promote apoptosis, 2) direct stimulation of
apoptosis pathway mechanism to caspasen
through TNF receptors, 3) apoptosis may be in-
duced by T lymphocytes (cytotoxic) and natural
killer cells, 4) proapoptotic and antiapoptotic pro-
teins that can stimulate or inhibit the induction of
apoptosis, such as the BCl2 family gene.7
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DNA damage in cells can induce apoptosis
through p53 pathway. DNA damage can be trig-
gered by various kinds of stimuli such as radiation
and drugs used in therapy kanker.12 Wild-type p53
is able to suppress cell transformation induced by
oncogenes and may inhibit potential tumoregenic
whereas p53 present in cells transformed a mutant
form p53.13
Under normal circumstances p53 tetramer con-
sisting of 4 identical copies, assembled into the
form of activated p53 molecule. The consequence
of a defect in one of the 4 subunit is it weakens the
function of proteins. And if the cell has 1 wild-type
allele and the other allele is defective, then the ma-
jority of p53 function will be compromised.13
Table 2 and 3 presented the effect of chemother-
apy on apoptotic index in early and advanced stage,
and it was not statistically significant but there was
an increase in apoptotic index after administration
of chemotherapy. The increasing apoptotic index
happened in 4 early stage cases (66.7%) and 6 ad-
vanced stage cases (66.7%). DNA damage in cells
caused by chemotherapy can induce apoptosis
through p53 (wild type), depending on the apop-
totic ability of wild-type p53. In the 1990’s, it was
known that p53 regulates the cell cycle checkpoint
which is responsible for DNA damage.
In the presence of DNA damage, p53 cells hold
for the next phase and allow time for the DNA to
make repairs, or if the damage is severe enough,
the p53 will initiate programmed cell death (apop-
tosis). A lost of several molecular checkpoints can
be found in the development of some tumors, this
is due to cell cycle progression to function prop-
erly. Accumulation of genetic changes also play a
role in the onset chemoresistant, which resulted in
the loss of ability to respond to DNA damage.7
In general, p53 mutations in one allele followed
by deletion of the other allele will caused both al-
leles to become inactive or not working. 17p dele-
tion allele occurred at least in 60% of colon, breast,
lung, ovarian, cervical cancer and at least 30% of
brain cancer. Most of the cancers that had 17p de-
letion allele contain mutant p53. This means that
p53 mutations occur during the process of tu-
morigenesis and that cancer grows through domi-
nantly negative effect.14 Loss of the lost of p53
function is frequently observed in cancer, thus
could be used as the basic of administering sub-
stance whose function is similar to the p53 gene.
In the future, it is likely that a more directed ther-
apy will be developed to replace the defective gene
through suicide gene therapy.12
In addition to p53 mutant as the cause of de-
creasing apoptotic index after chemotherapy, the
dose of medication could also have some effect. At
low doses, different types of stimuli such as high
temperature, radiation, hypoxia and anticancer cy-
tostatic can induce apoptosis, but in high doses, the
same stimulus may result in necrosis of the cell.12
Table 3 shows that the size change of the tumor
in response to chemotherapy in early-stage cervi-
cal carcinoma happened in 100% cases, and was
statistically significant. But in advanced cervical
carcinoma, we found that 3 cases (33.33%) expe-
rienced tumor shrinkage, 2 cases (22.22%) grew,
and 4 cases (44.44%) were fixed in size, and it was
not statistically significant. Kim (1988) conducted
a study on 35 patients of cervical carcinoma stage
Ib-IIa with PVBM regimen and 89% cases reported
to have a complete response. Sharvianty (2006) re-
ported 71 patients of advanced cervical carcinoma
treated with PVB-MMc. There were 22 cases that
showed a complete response (histopathological ex-
amination showed that there were no malignant
cells either in the cervix, uterus, adnexa and lymph
nodes), 40 cases assessed as partial response as the
original tumor is very exophytic and bulky (diame-
ter > 4 cm) and had become very small, but there
is still a process in the parametrium.
Administration of chemotherapy can cause tu-
mor regression so that it can be used as one meas-
ure to objectively assess the effectiveness of treat-
ment. Criteria for clinical effectiveness of treatment
include: complete response if the tumor mass has
disappeared on examination 4 weeks after 2 series
of chemotherapy. Partial response is a reduction in
the diameter of the largest tumor size and perpen-
dicular by 50% or more without any growth of new
lesions for 4 weeks. Tumors are stable if there is
no increase in tumor size or tumor shrink to the
size of a very minimal, and progressive lesions that
showed an increasing size of over 50% or the tu-
mor was found elsewhere.5
The increasing size of the tumor after chemo-
therapy can be caused by drug resistant (multidrug
resistance), which increased the presence of 170-
kDa transmembrane glycoprotein (P170 or glyco-
protein) which is the product of the MDR1 gene.
This glycoprotein plays a role in the mechanism of
drug efflux pumps. Increased expression of P170
glycoprotein causes an increase in the incidence of
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chemotherapy resistance. Due to the occurrence of
multiple mechanisms of resistance through the
mechanisms of DNA repair, drug accumulation due
to decreased influx mechanism, the process of in-
activation by glutathione, methalothion or inacti-
vation due to protein binding. It can be concluded
that the mechanism of chemotherapy resistance
through molecular cell review focused on two
genes that play a major role, namely wild-type p53
and Bcl2. P53 mutations will increase the resis-
tance of cells. Increased Bcl2 which acts as an in-
hibitor of apoptosis is also one of the mechanisms
of resistance to chemotherapy.7
A lot of literature written about 85-90% of cer-
vical carcinoma cell carcinoma squamousa mani-
fold, the rest is kind of different histology. Type of
cervical histopathology does not affect the apop-
totic index.
Apoptosis is strongly influenced by the p53
pathway. Research conducted in the laboratory
showed that HPV has a protein coat that produces
some oncoprotein. Oncoprotein E6 is an oncopro-
tein that affect p53 and can make it less or even
inactive. If the E6 oncoprotein is binding, it will
cause a mutagenesis effect on cell growth so that
the cell growth can not be controlled.11
CONCLUSION
PVB-MMc combination chemotherapy in cervical
carcinoma may increase the apoptotic index and
give a good clinical response to changes in tumor
size, although not statistically significant. Further
studies need to be done on mutant p53 as an im-
portant factor of the increasing apoptosis index.
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